In the dynamic landscape of global healthcare, Evinature has emerged as a pioneer with the recent launch of DivertX, a groundbreaking natural treatment designed specifically to treat the IBS-like symptoms of Post-Diverticulitis Syndrome (PDS). This innovative solution is poised to fill a crucial gap in diverticulitis care, offering a preventive strategy for patients experiencing lingering symptoms after acute episodes, a realm traditionally left untreated by existing options.
Evinature, renowned for its groundbreaking product CurQD®, has already established itself as a frontrunner in the healthcare startup scene. CurQD®, a pioneering nutraceutical, has improved the lives of those suffering from Inflammatory Bowel Disease (IBD). Building on this success, Evinature has now ventured into uncharted territory with DivertX, underscoring its commitment to addressing the multifaceted challenges faced by individuals with gastrointestinal disorders.
What is Diverticulitis?
Diverticulitis, a condition commonly addressed with antibiotics during acute episodes, often leaves patients without a clear plan for managing persistent symptoms that continue chronically after the acute attack.
“Digestive symptoms can linger after a diverticulitis attack, but patients are often left without a clear diagnosis or are misdiagnosed with IBS, and are ultimately left without any solution addressing their needs, which not only places a burden on the healthcare system but lowers their quality of life and leaves many to fall through the cracks,” states Nir Salomon, Co-Founder and Head of R&D at Evinature.
As diverticulitis remains an underexplored disease with limited research on treatment options, researchers are turning to compounds with anti-inflammatory effects, antimicrobial action, and the ability to modulate the intestinal microbiome. Two natural herbal treatments under investigation, curcumin and coptis, have shown promise in improving patient outcomes and relieving post-episode lingering symptoms.
How Does DivertX Work?
Curcumin, a key component of DivertX, demonstrates significant benefits for those with acute diverticulitis. Patients with this condition often exhibit mucosal inflammation due to immune system activation, with increased expression of TNFα being a marker. Curcumin has been shown to inhibit TNFα, a critical inflammatory chemical associated with acute diverticulitis. Additionally, curcumin aids in restoring gut microbiome balance, addressing dysbiosis linked to diverticulitis progression.
DivertX's unique formula combines two herbal compounds, Curcuma Longa and Coptis Chinensis, to target mucosal inflammation, bacterial imbalance, and IBS-like symptoms associated with PDS. Curcuma Longa, with its curcumin content, focuses on intestinal inflammation, fortifying the intestinal barrier, and improving gut bacteria balance. Coptis Chinensis, containing Berberine, regulates butyrate production, a natural compound clinically found to reduce episodes of diverticulitis.
To identify individuals with PDS, Evinature provides clear indicators: a history of acute diverticulitis episodes, incomplete recovery of the digestive system post-episode, and the manifestation of IBS-like symptoms such as bloating, abdominal discomfort, or irregular bowel movements.
“This treatment evolved out of an unmet medical need and a pre-existing demand from both doctors and patients,” Nir continues. “The DivertX formula was actually developed for post-infectious IBS, but a leading doctor asked if it might also help Post-Divertiticilis Syndrome, so we took it to trial. We saw that patients who had suffered severe chronic symptoms for a long time were able to finally find some relief. We saw significant improvement in abdominal pain, alternating bowel movements, and bloating, and many patients were extremely eager to continue treatment after Phase 1.”
What’s Next for DivertX?
Evinature is currently in phase 2 of their ongoing clinical trial for DivertX, building on the success of their phase 1 study where 70% of patients reported improvement and requested continuation due to positive results. These promising outcomes position DivertX as a potential game-changer in post-diverticulitis syndrome treatment, offering patients a natural and effective option for managing post-episode symptoms.
With its innovative approach and promising clinical trial results, DivertX could pave the way for a paradigm shift in diverticulitis care, providing a holistic solution for patients in need.
DivertX will be available in tailored programs on Evinature.com from the 1st of February.
To learn more about Evinature, visit this link.